Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects

Human Gene Therapy

Volumn 27, Issue 4, 2016, Pages 295-304

  Mansilla Soto, Jorge ^a   Riviere, Isabelle ^a   Boulad, Farid ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DOUBLE STRANDED DNA; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HIGH MOBILITY GROUP A2 PROTEIN; LENTIVIRUS VECTOR; OLIGODEOXYNUCLEOTIDE; PLASMID DNA; RETROVIRUS VECTOR; SINGLE STRANDED DNA; TRANSCRIPTION FACTOR GATA 1; GLOBIN;

ARTICLE; BETA THALASSEMIA; BINDING SITE; BLOOD TRANSFUSION; CELL THERAPY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA END JOINING REPAIR; DNA REPAIR; DNA SEQUENCE; DNA TEMPLATE; DNA TRANSFECTION; ENHANCER REGION; ERYTHROBLAST; ERYTHROPOIESIS; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC VARIABILITY; GENOME; GENOME EDITING; GENOME-WIDE ASSOCIATION STUDY; GENOMIC INSTABILITY; GLOBIN GENE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRON; LEUKEMIA; LONG TERMINAL REPEAT; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PROMOTER REGION; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; WILD TYPE; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ZINC FINGER MOTIF; ADVERSE EFFECTS; ANIMAL; BETA-THALASSEMIA; CLINICAL TRIAL (TOPIC); GENE EDITING; GENETICS;

ANIMALS; BETA-THALASSEMIA; CLINICAL TRIALS AS TOPIC; GENE EDITING; GENETIC THERAPY; GLOBINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84964608766     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.037     Document Type: Article

References (80)

1. Stamatoyannopoulos G, Nienhuis AW, Majerus P, Varmus H, eds. The Molecular Basis of Blood Diseases. (WB Saunders, Philadelphia, PA). 2001.
2. Sadelain M, Boulad F, Galanello R, et al. Therapeutic options for patients with severe betathalassemia: The need for globin gene therapy. Hum Gene Ther 2007;18:1-9.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
4. Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009;94:1777-1778.
5. Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusiondependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol 2011;86:332-338.
6. Mancuso A, Sciarrino E, Renda MC, et al. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30:119-124.
7. Persons DA, Tisdale JF. Gene therapy for the hemoglobin disorders. Semin Hematol 2004;41: 279-286.
8. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol 2006;13: 142-148.
9. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-86.
10. Li Q, Peterson KR, Fang X, et al. Locus control regions. Blood 2002;100:3077-3086.
11. May C, Rivella S, Chadburn A, et al. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002;99:1902-1908.
12. Rivella S, May C, Chadburn A, et al. A novel murine model of Cooley anemia and its rescue by lentiviralmediated human beta-globin gene transfer. Blood 2003;101:2932-2939.
13. Sadelain M, Boulad F, Lisowki L, et al. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr Mol Med 2008;8:690-697.
14. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3:477-488.
15. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
16. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.
17. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150.
18. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med 2014;6: 233-227.
19. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: The rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther 2007;15: 445-456.
20. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for betathalassemia. Ann N Y Acad Sci 2005;1054:308-316.
21. Boulad F, Wang X, Qu J, et al. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood 2014;123:1483-1486.
22. Li K, Wong A, Li CK, et al. Granulocyte colonystimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: Kinetics of mobilization and composition of apheresis product. Exp Hematol 1999;27:526-532.
23. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: Results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012;20:230-238.
24. Recombinant DNA Advisory Committee. Minutes of Meeting, June 19-21. http://osp.od.nih.gov/sites/default/files/RAC-minutes-06-07.pdf. 2007: 14-18
25. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-322.
26. Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene. Hum Gene Ther 2016;27:148-165.
27. Cavazzana M. Outcomes of gene therapy for bthalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral bA T87Q-globin vector [abstract]. Presented at the Tenth Cooley's Anemia Symposium, Chicago, IL, October 18-22, 2015. www.nyas.org/Events/Detail.aspx?cid=244781db-3089-4f17-8addf16c73d821fb
28. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-409.
29. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204.
30. Boulad F,Maggio A,Wang X, et al. Gene Therapy for beta-thalassemia major: The Memorial Sloan Kettering experience [abstract]. Presented at the Tenth Cooley's Anemia Symposium, Chicago, IL, October 18-22, 2015. www.nyas.org/Events/Detail.aspx? cid=244781db-3089-4f17-8add-f16c73d821fb
31. Phillips-Cremins JE, Corces VG. Chromatin insulators: Linking genome organization to cellular function. Mol Cell 2013;50:461-474.
32. Giles KE, Gowher H, Ghirlando R, et al. Chromatin boundaries, insulators, and long-range interactions in the nucleus. Cold Spring Harb Symp Quant Biol 2010;75:79-85.
33. Emery DW, Yannaki E, Tubb J, et al. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 2000;97:9150-9155.
34. Emery DW, Yannaki E, Tubb J, et al. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002;100:2012-2019.
35. Rivella S, Callegari JA, May C, et al. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000;74:4679-4687.
36. Liu M, Maurano MT, Wang H, et al. Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 2015;33:198-203.
37. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci USA 2008;105:10547-10552.
38. Lidonnici MR, Aprile A, Paleari Y, et al. Update on gene therapy clinical trial for the treatment of beta thalassemia major in Italy [abstract]. Presented at the Tenth Cooley's Anemia Symposium, Chicago, IL, October 18-22, 2015. www.nyas.org/Events/Detail.aspx?cid=244781db-3089-4f17-8addf16c73d821fb
39. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther 2016;24:430-446.
40. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the doublestrand break. Trends Cell Biol 2016;26:52-64.
41. Jasin M, Rothstein R. Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol 2013;5:a012740.
42. Rouet P, Smih F, Jasin M. Introduction of doublestrand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol 1994;14:8096-8106.
43. Chandrasegaran S, Carroll D. Origins of programmable nucleases for genome engineering. J Mol Biol 2016;428:963-989.
44. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014;15:321-334.
45. Fagerlund RD, Stalals RHJ, Fineran PC. The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biol 2016;16:251-253.
46. Thakore PI, Black JB, Hilton IB, et al. Editing the epigenome: Technologies for programmable transcription and epigenetic modulation. Nat Methods 2016;13:127-137.
47. Hotta A, Yamanaka S. From genomics to gene therapy: Induced pluripotent stem cells meet genome editing. Annu Rev Genet 2015;49:47-70.
48. Renaud JB, Boix C, Charpentier M, et al. Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPRCas9 nucleases. Cell Rep 2016;14:2263-2272.
49. Gabriel R, von Kalle C, Schmidt M. Mapping the precision of genome editing.Nat Biotechnol 2015;33: 150-152.
50. Ishida K, Gee P, Hotta A. Minimizing off-target mutagenesis risks caused by programmable nucleases. Int J Mol Sci 2015;16:24751-24771.
51. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510:235-240.
52. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015;125: 2597-2604.
53. Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 2015;7: 307ra156.
54. Wang J, Exline CM, DeClercq JJ, et al. Homologydriven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 2015;33:1256-1263.
55. MaN, Liao B, Zhang H, et al. Transcription activatorlike effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. J Biol Chem 2013; 288:34671-34679.
56. Sebastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011;29:1717-1726.
57. Voit RA, Hendel A, Pruett-Miller SM, et al. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucleic Acids Res 2014;42:1365-1378.
58. Xie F, Ye L, Chang JC, et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014;24:1526-1533.
59. Xu P, Tong Y, Liu XZ, et al. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C < T) mutation in beta-thalassemia-derived iPSCs. Sci Rep 2015;5:12065.
60. Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011;118:4599-4608.
61. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci 1998;850:38-44.
62. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. (Blackwell Science, Oxford, UK). 2001.
63. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008;105:11869-11874.
64. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zincfinger protein on chromosome 2p15. Nat Genet 2007;39:1197-1199.
65. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008;105:1620-1625.
66. Bauer DE, Orkin SH. Hemoglobin switching's surprise: The versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev 2015;33:62-70.
67. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-1842.
68. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009;460:1093-1097.
69. Nuinoon M, Makarasara W, Mushiroda T, et al. A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum Genet 2010;127:303-314.
70. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013;342:253-257.
71. Vierstra J, Reik A, Chang KH, et al. Functional footprinting of regulatory DNA. Nat Methods 2015;12:927-930.
72. Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 2015;527:192-197.
73. Perez-Pinera P, Kocak DD, Vockley CM, et al. RNAguided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 2013;10: 973-976.
74. Hilton IB, D'Ippolito AM, Vockley CM, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 2015;33:510-517.
75. Deng W, Rupon JW, Krivega I, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell 2014;158:849-860.
76. McNeer NA, Schleifman EB, Cuthbert A, et al. Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Ther 2013;20:658-669.
77. Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 2011;22: 761-774.
78. Brady T, Roth SL, Malani N, et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 2011;39:e72.
79. Schmidt M, Schwarzwaelder K, Bartholomae C, et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007;4:1051-1057.
80. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979;76:670-672.